Viimeisimmät artikkelit
- Enrolment completed in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
- Kutsu Desentum Oy:n ylimääräiseen yhtiökokoukseen / Summons to Extraordinary General Meeting of Desentum Oy
- Dosing started in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
- Phase 2 trial for birch pollen allergy treatment DM-101PX approved by Health Canada
- Desentum to present clinical results of investigational birch pollen allergy vaccine DM-101PX and scientific discoveries about peanut allergy at the world’s largest allergy congress
Viimeisimmät kommentit
No comments to show.